Trex Bio Inc(TRXB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 55.62% | Shs Outstand | 27.4M | Perf Week | 9.46% |
| Market Cap | 0.43B | Forward P/E | - | EPS next Y | - | Insider Trans | 1.18% | Shs Float | 12.2M | Perf Month | - |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | 4.58% | Short Float | - | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | - | Perf YTD | 14.81% |
| Book/sh | - | P/C | - | EPS past 3/5Y | - | ROE | - | 52W High | -6.41% ($16.56) | Perf Year | - |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 17.34% ($13.21) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 9.55% - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | - | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | 8.18% ($14.33) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | 8.18% ($14.33) | Rel Volume | 0.25 | Prev Close | $15.24 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | 8.18% ($14.33) | Avg Volume(3M) | 0.27M | Price | $15.5 |
| IPO | 2026/10/9 | Option/Short | No/Yes | Trades | 1704 | Volume | 67,501 | Change | 1.71% |
🧬 트렉스 바이오는 조직에 머무는 조절 T세포의 생물학을 바탕으로 면역 균형 회복과 조직 복구를 돕는 면역조절 신약을 개발하는 임상 단계 바이오테크 기업입니다. 미국에 본사를 두고 있으며, 자가면역·염증 질환 환자의 미충족 수요를 겨냥합니다. 선두 후보물질은 염증 조직의 조절 T세포를 늘리고 활성화하도록 설계된 종양괴사인자 수용체2 작용제입니다.
Over the past 1 year, roughly in the middle
6% below its 1-year high.
Traded less than usual. That is 25% of its average volume.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.6%.
Tap to view numbers
It ranks #233 of 594 in the industry
Based on market cap of $425M.
FAQ
What kind of company is TRXB?
TRXB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TRXB?
The market cap of TRXB is approximately $425M, ranking 3,290 within its sector.
What is the 52-week high and low for TRXB?
TRXB has recorded a 52-week high of $16.56 and a low of $13.21.
